PREVENAR 20

(pneumococcal 20-valent conjugate vaccine - diphtheria CRM197 protein)

Find PREVENAR 20 medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREVENAR 20 Quick Finder

▼ This medicinal product is subject to additional monitoring, which will allow the rapid identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

The Prevenar 20 Summary of Product Characteristics (SmPC) is available here.

Prevenar 20 is indicated for:

Active immunisation for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children, and adolescents from 6 weeks to less than 18 years of age.
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.

Prevenar 20 should be used in accordance with official recommendations.

Didn’t find what you were looking for?

Contact us

Call 01 58 07 34 40*

*Contact Medical Information. 09h - 18h Monday to Friday.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at FRA.AEReporting@pfizer.com.

Governmental website

You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr